What Will Happen to Adaptimmune Therapeutics Plc – American Depositary (NASDAQ:ADAP) Next? The Stock Has Decline in Shorts

March 17, 2018 - By Vivian Currie

 What Will Happen to Adaptimmune Therapeutics Plc   American Depositary (NASDAQ:ADAP) Next? The Stock Has Decline in Shorts

The stock of Adaptimmune Therapeutics Plc – American Depositary (NASDAQ:ADAP) registered a decrease of 32.52% in short interest. ADAP’s total short interest was 1.07M shares in March as published by FINRA. Its down 32.52% from 1.59 million shares, reported previously. With 851,500 shares average volume, it will take short sellers 1 days to cover their ADAP’s short positions. The short interest to Adaptimmune Therapeutics Plc – American Depositary’s float is 2.33%.

The stock increased 1.10% or $0.12 during the last trading session, reaching $11.06. About 1.38M shares traded or 156.94% up from the average. Adaptimmune Therapeutics plc (NASDAQ:ADAP) has declined 43.56% since March 17, 2017 and is downtrending. It has underperformed by 60.26% the S&P500.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. The company has market cap of $1.04 billion. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients. It currently has negative earnings. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings Coverage

Among 7 analysts covering Adaptimmune Therapeutics PLC (NASDAQ:ADAP), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Adaptimmune Therapeutics PLC has $20.0 highest and $10.0 lowest target. $15’s average target is 35.62% above currents $11.06 stock price. Adaptimmune Therapeutics PLC had 8 analyst reports since February 25, 2016 according to SRatingsIntel. On Thursday, February 25 the stock rating was initiated by Citigroup with “Buy”. The firm has “Buy” rating by Cowen & Co given on Tuesday, June 6. The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) has “Buy” rating given on Friday, March 16 by Leerink Swann. The rating was maintained by Cowen & Co on Friday, March 16 with “Buy”. Bank of America downgraded the stock to “Underperform” rating in Monday, October 24 report. The company was maintained on Saturday, November 11 by SunTrust.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.